GRDN Guardian Pharmacy Services, Inc.
Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services to help residents of long-term health care facilities (LTCFs) in the United States. The company's individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities, behavioral health facilities, and group homes. Its Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; GuardianShield Programs for LTCFs; Order Entry QA Analyzer, which utilizes real-time rules- engine technology to examine prescriptions and detect omissions and/or errors before they become a customer service problem; and Medication Spend Analyzer to break down the monthly drug spending for each of the LTCFs. Guardian Pharmacy Services, Inc. was founded in 2003 and is headquartered in Atlanta, Georgia.…
Industry Peers
Medical Care FacilitiesKey Statistics
About Guardian Pharmacy Services (NYSE: GRDN)
›
Guardian Pharmacy Services (NYSE: GRDN) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Medical Care Facilities industry, part of the Healthcare sector, and reports about 3,600 employees.
The shares were at 46.67 USD on 19 November 2026, up 67.2% over 52 weeks. Its 52-week range is 26.34 USD to 50.80 USD: the price is 8.1% below the high and 77.2% above the low.
At a market capitalisation of 2.96B USD, it trades at 39.9 times trailing earnings and 31.1 times forward earnings. The median trailing P/E of its 18 largest Medical Care Facilities peers is 22.0, a premium of 81% for GRDN.
Guardian Pharmacy Services reports return on equity of 23.9%, an operating margin of 6.5% and revenue down 1.7% year over year.
It holds more cash than debt, a net cash position of 79.06M USD. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 7 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 51.29 USD is 9.9% above the current price. The next earnings report is expected on 11 March 2027.